Wolwo Pharma(300357.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Wolwo Pharma
300357.SZ
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of diagnostic and therapeutic products for allergic diseases in China and internationally. The company offers Changdi, a skin prick test product and dust mite drops; Changhao, an Artemisia annua pollen allergen sublingual drop; and Changdian, a dust mite skin prick test diagnostic kit. It is also involved in the research and development of cells and natural medicines.
2.805 T
300357.SZMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking23/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE16.48%A
    • Profit Margin39.18%A
    • Gross Margin95.25%A
  • Growth ScoreB
    • Revenue YoY15.91%B
    • Net Profit YoY35.20%B
    • Total Assets YoY9.75%B
    • Net Assets YoY11.73%B
  • Cash ScoreB
    • Cash Flow Margin92.14%C
    • OCF YoY15.91%B
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreA
    • Gearing Ratio3.71%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Wolwo Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 345 million yuan, an increase of 26.67%

    Zhitong·
    SZ
    300357
    -1.01%
    Zhitong·
    SZ
    300357
    -1.01%

    A-share innovative drug concept stocks fluctuated and rose, Wolwo Pharma increased by over 10%, Chemexpress rose by over 9%, Fushine, CSBIO, and Medicilon followed suit

    Zhitong·
    SZ
    300357
    -1.01%
    SZ
    300255
    -1.78%
    SH
    688131
    +1.05%
    Zhitong·
    SZ
    300357
    -1.01%
    SZ
    300255
    -1.78%
    SH
    688131
    +1.05%

    Wolwo Pharma obtained the summary report of Phase I clinical trial for Aspergillus flavus puncture solution

    Zhitong·
    SZ
    300357
    -1.01%
    Zhitong·
    SZ
    300357
    -1.01%

    Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launch

    Zhitong·
    SZ
    300357
    -1.01%
    Zhitong·
    SZ
    300357
    -1.01%

    Zhongtai Securities: Maintain Wolwo Pharma "Buy" rating, steady revenue growth, core products continue to expand

    Zhitong·
    SZ
    300357
    -1.01%
    Zhitong·
    SZ
    300357
    -1.01%
    © 2026 Longbridge｜Disclaimer